Opioids, Short-Acting

• Opioids Literature Scan - Apr 01, 2021
• Opioids Literature Scan - Feb 06, 2020
• Opioids - Sep 26, 2019
• Opioid Analgesics - Nov 17, 2016
• Short-acting Opioids - May 28, 2015
• Short-Acting Opioids (SAOs) - Jul 25, 2013

• Short-acting Opioid Days' Supply Limits - Apr 01, 2021
• Concurrent Use of Opioids and CNS depressants - Jul 25, 2019
• Codeine Drug Use Review - Jul 30, 2015
• Drug Use Evaluation: Tapentadol - Mar 28, 2013
• Drug Use Evaluation: Short-Acting Opioids - Mar 29, 2012

• November 2019 - Update on Recent Guidance and Safety Alerts for Opioid Use in Non-cancer Pain
• July 2017 - Tramadol and Codeine Use In Pediatrics: A Review of Recent FDA Safety Alerts
• December 2016 - Guideline and Policy Updates for Use of Opioids for Non-Cancer Pain and Opioid Use Disorder
• February 2016 - 2015 in Review: Relevant Safety Updates and Ongoing Safety Concerns
• March 2015 - Combating the Opioid Epidemic: Are Abuse-deterrent Formulations the Answer?

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.